Literature DB >> 32536829

Postoperative radio-chemotherapy for rectal cancer: A retrospective analysis from a tertiary referral hospital.

Ewa Wasilewska-Teśluk1,2, Monika Rucińska2,3, Karolina Osowiecka4,5, Iwona Ryniewicz-Zander6, Beata Czeremszyńska3, Krzysztof Gliński1, Lucyna Kępka3.   

Abstract

AIM: To report results of postoperative radio-chemotherapy (RT-CHT) for rectal cancer (RC).
BACKGROUND: Total mesorectal excision (TME) is an essential treatment method in rectal cancer (RC). Perioperative radiotherapy in locally advanced RC improves loco-regional free survival (LRFS). Preoperative radiotherapy is a preferred option; however, some patients are not referred for it. In case of the risk of loco-regional failure postoperative radio-chemotherapy (RT-CHT) is indicated.
MATERIAL AND METHODS: Between 2004 and 2010, 182 patients with pathological stage II-III RC (TME performed - 41%, resection R0 - 88%, circumferential resection margin evaluated - 55.5% and was above 2 mm in 66% of them) received postoperative RT-CHT in our institution. Overall survival (OS) and LRFS were estimated with the Kaplan-Meier method. Univariate and multivariate analysis were performed to compare the impact of prognostic factors on survival.
RESULTS: Five-year OS and LRFS rates were 63% and 85%, respectively. Loco-regional recurrence and isolated distant metastases rates were 11.5% and 19%, respectively. Multivariate analysis showed stage (III vs. II), HR: 2.3 (95% confidence interval [CI]: 1.4-3.8), p = 0.0001; extent of resection (R1-2 vs. R0), HR: 2.14 (95%CI: 1.14-3.99), p = 0.017, and age (>65 vs. ≤65 years), HR: 1.66 (95%CI: 1.06-2.61), p = 0.027 as prognostic factors for OS. Extent of resection (R1-2 vs. R0), HR: 3.65 (95%CI: 1.41-9.43), p = 0.008 had significant impact on LRFS.
CONCLUSION: Despite a suboptimal quality of surgery and pathological reports, the outcome in our series is close to that reported in the literature. We confirm a strong impact of the extent of resection on patient's outcome, which confirms the pivotal role of surgery in the management of RC.
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Postoperative radio-chemotherapy; Rectal cancer; Total mesorectal excision

Year:  2020        PMID: 32536829      PMCID: PMC7276489          DOI: 10.1016/j.rpor.2020.05.002

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  26 in total

1.  Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer.

Authors:  A Wibe; P R Rendedal; E Svensson; J Norstein; T J Eide; H E Myrvold; O Søreide
Journal:  Br J Surg       Date:  2002-03       Impact factor: 6.939

2.  Relation of surgeon and hospital volume to processes and outcomes of colorectal cancer surgery.

Authors:  Selwyn O Rogers; Robert E Wolf; Alan M Zaslavsky; William E Wright; John Z Ayanian
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

3.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  B Glimelius; E Tiret; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

4.  The quality of pathological reports of postoperative specimens in rectal cancer: an audit from the Mazovia region.

Authors:  Marta Olszyna-Serementa; Milena Kołodziejczyk; Arkadiusz Sprawka; Anna Nasierowska-Guttmejer; Krzysztof Bujko
Journal:  Pol J Pathol       Date:  2009       Impact factor: 1.072

5.  Postoperative 5-FU based radiochemotherapy in rectal cancer: retrospective long term results and prognostic factors of a pooled analysis on 1,338 patients.

Authors:  Domenico Genovesi; Robert J Myerson; Giampiero Ausili Cèfaro; Annamaria Vinciguerra; Antonietta Augurio; Marianna Trignani; Monica DI Tommaso; Marianna Nuzzo; Marco Lupattelli; Cynthia Aristei; Rita Bellavita; Luciano Scandolaro; Dorian Cosentino; Giuseppe Pani; Luigi Ziccarelli; Maria A Gambacorta; Maria C Barba; Ernesto Maranzano; Fabio Trippa; Piera Sciacero; Rita Niespolo; Cristina Leonardi; Tiziana Iannone; Maria Elena Rosetto; Vincenzo Fusco; Piero Sanpaolo; Antonella Melano; Francesca Valvo; Carlo Capirci; Antonino DE Paoli; Marta DI Nicola; Giovanna Mantello; Vincenzo Valentini
Journal:  Anticancer Res       Date:  2013-10       Impact factor: 2.480

6.  Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials.

Authors:  Vincenzo Valentini; Ruud G P M van Stiphout; Guido Lammering; Maria Antonietta Gambacorta; Maria Cristina Barba; Marek Bebenek; Franck Bonnetain; Jean-Francois Bosset; Krzysztof Bujko; Luca Cionini; Jean-Pierre Gerard; Claus Rödel; Aldo Sainato; Rolf Sauer; Bruce D Minsky; Laurence Collette; Philippe Lambin
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544

7.  Recurrence and survival after total mesorectal excision for rectal cancer.

Authors:  R J Heald; R D Ryall
Journal:  Lancet       Date:  1986-06-28       Impact factor: 79.321

8.  Circumferential margin involvement after mesorectal excision of rectal cancer with curative intent. Predictor of survival but not local recurrence?

Authors:  N R Hall; P J Finan; T al-Jaberi; C S Tsang; S R Brown; M F Dixon; P Quirke
Journal:  Dis Colon Rectum       Date:  1998-08       Impact factor: 4.585

9.  The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.

Authors:  Koen C M J Peeters; Corrie A M Marijnen; Iris D Nagtegaal; Elma Klein Kranenbarg; Hein Putter; Theo Wiggers; Harm Rutten; Lars Pahlman; Bengt Glimelius; Jan Willem Leer; Cornelis J H van de Velde
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

10.  Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision.

Authors:  P Quirke; P Durdey; M F Dixon; N S Williams
Journal:  Lancet       Date:  1986-11-01       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.